Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase...
Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau ® Net...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial...
Leerink Partners analyst Marc Goodman maintained a Buy rating on Evolus on October 7. The company’s shares closed yesterday at $6.23.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase...
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial...
Evolysse ™ Sculpt met the primary endpoint of non-inferiority and demonstrated statistical superiority to Restylane ...